Bezuclastinib
Cogent Biosciences (COGT)
Decision dateNov 30, 2026
15 days away
Marketer take
The company says it is preparing to launch in GIST, a disease treated by a small group of sarcoma-focused oncologists, so competing GIST brands should expect concentrated, sequencing-focused messaging at the same centers.
- Sponsor company
- Cogent Biosciences (COGT)
- Indication
- Gastrointestinal stromal tumor (GIST)
- Therapeutic area
- Oncology
- Event
- PDUFA target action date
- Date
- Nov 30, 2026
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?